NASDAQ:MNTA
Delisted
Momenta Pharmaceuticals Stock News
$52.48
+0 (+0%)
At Close: May 27, 2022
Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Tops Revenue Estimates
01:05pm, Monday, 10'th Aug 2020
Momenta (MNTA) delivered earnings and revenue surprises of -14.29% and 13.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Momenta Pharmaceuticals Q2 Earnings
11:27am, Monday, 10'th Aug 2020
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) rose 1% after the company reported Q2 results.Quarterly Results Earnings per share increased 58.62% year over year to ($0.48), which missed the estimate
Momenta Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results
11:00am, Monday, 10'th Aug 2020
\-- Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p<0.0001) between IgG
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Nisa Investment Advisors LLC Acquires 19,390 Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
06:30am, Wednesday, 05'th Aug 2020
Nisa Investment Advisors LLC boosted its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 321.0% in the 2nd quarter, according to its most recent disclosure with the Securities and
World Retinal Biologics Market: Growth, Trends and Forecasts (2020-2025) - ResearchAndMarkets.com
12:00am, Tuesday, 04'th Aug 2020
The
Momenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and Webcast
11:30am, Monday, 03'rd Aug 2020
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat ra
FY2022 EPS Estimates for Momenta Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:MNTA)
02:32am, Sunday, 02'nd Aug 2020
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) – Investment analysts at Piper Sandler lowered their FY2022 earnings per share (EPS) estimates for shares of Momenta Pharmaceuticals in a research report
Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:30pm, Friday, 31'st Jul 2020
Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN
11:15am, Tuesday, 28'th Jul 2020
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease designa
Will Momenta Pharmaceuticals (NASDAQ:MNTA) Spend Its Cash Wisely?
07:04pm, Friday, 24'th Jul 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Charting a bull-flag breakout, S&P 500 extends rally as volatility recedes
04:24pm, Tuesday, 21'st Jul 2020
Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish, and continues to strengthen, amid recently receding volatility, writes...
IPO Update: Annexon Proposes IPO Terms
02:32pm, Monday, 20'th Jul 2020
Annexon has filed to raise $150 million in an IPO of its common stock. The firm is developing treatments for autoimmune and neurodegenerative diseases.
Continua la corsa ai Robotaxi: i primi esperimenti di Elon Musk
12:00am, Monday, 20'th Jul 2020
Continua la corsa ai Robotaxi: i primi esperimenti di Elon Musk
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Shares Purchased by Louisiana State Employees Retirement System
06:20pm, Thursday, 16'th Jul 2020
Louisiana State Employees Retirement System grew its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 17.2% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned
